tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Albano L et al. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. 2013 Transplantation pmid:23982340
Farid SG et al. Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. 2009 Transplantation pmid:19502974
Nakamura Y et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. 2003 Transplantation pmid:12717187
Boukriche Y et al. Severe axonal polyneuropathy after a FK506 overdosage in a lung transplant recipient. 2001 Transplantation pmid:11740402
Guethoff S et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. 2013 Transplantation pmid:23423270
Yun J et al. Bilateral ischemic optic neuropathy in a patient using tacrolimus (FK506) after liver transplantation. 2010 Transplantation pmid:20559109
Anderson PO Tacrolimus and breastfeeding. 1998 Transplantation pmid:9539100
Berenguer M et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. 2010 Transplantation pmid:21068701
Propper DJ et al. FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. 1990 Transplantation pmid:1696409
Migita K et al. FK506 potentiates steroid-induced T-cell apoptosis. 1997 Transplantation pmid:9371682
Fabrega AJ et al. Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. 1993 Transplantation pmid:7506458
Jain A et al. FK506 and pregnancy in liver transplant patients. 1993 Transplantation pmid:7506459
Sankary HN et al. FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. 1998 Transplantation pmid:9798690
Sofi AA et al. Bullous pemphigoid associated with acute renal allograft rejection. 2010 Transplantation pmid:20145531
Ito A et al. Donor-specific tolerance by perioperative intrathymic injection of bone marrow cells in the rat cardiac allograft model: use of FK506 can shorten the necessary duration of pretransplant intrathymic conditioning. 1997 Transplantation pmid:9311715
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. 2006 Transplantation pmid:16570006
Barten MJ et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. 2004 Transplantation pmid:15114077
Uryuhara K et al. Thymectomy impairs but does not uniformly abrogate long-term acceptance of semi-identical liver allograft in inbred miniature Swine temporarily treated with FK506. 2004 Transplantation pmid:15114080
Gruessner RW et al. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. 1997 Transplantation pmid:9415558
First MR et al. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. 2013 Transplantation pmid:23619735
Pruvot FR and Noel C Comment on "Pregnancy after liver transplantation under tacrolimus" by Jain et al. 1998 Transplantation pmid:9625033
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Xie Y et al. Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. 2017 Transplantation pmid:28187014
Shimada T et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. 2002 Transplantation pmid:12451243
Vignali D et al. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody. 2016 Transplantation pmid:27306531
Calandra S Sinus arrest during tacrolimus treatment: was the QT interval prolonged? 1998 Transplantation pmid:9721813
Nakata Y et al. Tacrolimus and myocardial hypertrophy. 2000 Transplantation pmid:10830241
Nguyen L et al. Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients. 2012 Transplantation pmid:22960763
Beckebaum S et al. Predictive factors of outcome in patients transplanted for hepatitis B. 2009 Transplantation pmid:19300191
Marks WH et al. Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes. 1997 Transplantation pmid:9020333
Pascual J et al. Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. 2011 Transplantation pmid:21336083
Fujishiro J et al. Immunologic benefits of longer graft in rat allogenic small bowel transplantation. 2005 Transplantation pmid:15665767
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Hricik DE et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. 2002 Transplantation pmid:12151730
Kainz A et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. 2000 Transplantation pmid:11152103
Krähenbühl S et al. Serious interaction between mibefradil and tacrolimus. 1998 Transplantation pmid:9808502
Wissing KM et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. 2006 Transplantation pmid:17006324
Hoerning A et al. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. 2015 Transplantation pmid:25099702
Tsamandas AC et al. Central venulitis in the allograft liver: a clinicopathologic study. 1997 Transplantation pmid:9256183
Peduto G et al. Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression. 2000 Transplantation pmid:10919579
Vadivel N et al. Tacrolimus dose in black renal transplant recipients. 2007 Transplantation pmid:17460575
López Lago AM et al. Evolution of hepatorenal syndrome after orthotopic liver transplantation: comparative analysis with patients who developed acute renal failure in the early postoperative period of liver transplantation. 2007 Transplant. Proc. pmid:17889176
Loinaz C et al. A single-centre experience with cyclosporine microemulsion versus tacrolimus in 100 randomized liver transplant recipients: midterm efficacy and safety. 2001 Nov-Dec Transplant. Proc. pmid:11750472
Rostaing L et al. Early posttransplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. 1998 Transplant. Proc. pmid:9636519
Perrakis A et al. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome. 2011 Transplant. Proc. pmid:22172830
Kinoshita I et al. Immunosuppression with FK 506 insures good success of myoblast transplantation in MDX mice. 1994 Transplant. Proc. pmid:7527978
Wong KM et al. Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study. 2000 Transplant. Proc. pmid:11119907
Porayko MK et al. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. 1993 Transplant. Proc. pmid:7679835
Iwasaki K et al. Pharmacokinetic study of FK 506 in the rat. 1991 Transplant. Proc. pmid:1721268
Andersson J et al. FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. 1992 Transplant. Proc. pmid:1371621
Takada S et al. HGF prevents tacrolimus (FK 506)-induced nephrotoxicity in SHR rats. 1996 Transplant. Proc. pmid:8623236
Monden M et al. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. 1990 Transplant. Proc. pmid:1689904
Ciancio G et al. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. 2003 Transplant. Proc. pmid:12644172
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients treated with tacrolimus. 2002 Transplant. Proc. pmid:11959335
Steinmueller T et al. Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. 1998 Transplant. Proc. pmid:9636589
Miura S et al. The beneficial effects of FK 506 on living-related renal transplantation in presensitized recipients. 1999 Transplant. Proc. pmid:10455940
Ringe B et al. Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11120285
Alloway RR et al. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. 1996 Transplant. Proc. pmid:8623494
Dumont FJ et al. Up-regulation of gene expression by FK 506. 1991 Transplant. Proc. pmid:1721300
Koefoed-Nielsen PB et al. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. 2005 Transplant. Proc. pmid:15919449
Jain A et al. Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. 1992 Transplant. Proc. pmid:1376518
Watanabe K et al. Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. 1995 Transplant. Proc. pmid:7533389
Kitamura T et al. Severe hemolytic anemia related to production of cold agglutinins following living donor liver transplantation: a case report. 2003 Transplant. Proc. pmid:12591458
Borg AJ and Kumagai M FK 506 and xenogeneic human anti-porcine cellular reactivity. 1991 Transplant. Proc. pmid:1721332
Lladó L et al. Prospective study of a tacrolimus-based quadruple immunosuppressive regimen: evaluation of safety and efficacy. 2002 Transplant. Proc. pmid:12176468
Fleck PR et al. Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine. 1998 Transplant. Proc. pmid:9865299
Niel OR et al. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors. 2009 Transplant. Proc. pmid:19857743
Regazzi MB et al. Pharmacokinetics of FK506 and mycophenolic acid in experimental and clinical intestinal transplantation. 1997 Transplant. Proc. pmid:9142302
Oltean M et al. FK506 donor pretreatment improves intestinal graft microcirculation and morphology by concurrent inhibition of early NF-kappaB activation and augmented HSP72 synthesis. 2005 Transplant. Proc. pmid:15919508
Lemster B et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. 1992 Transplant. Proc. pmid:1281576
Jensen CW et al. Pediatric renal transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721364
McCauley J et al. The question of FK 506 nephrotoxicity after liver transplantation. 1991 Transplant. Proc. pmid:1703344
Ciancio G et al. Effect of daclizumab, tacrolimus and mycophenolate mofetil in racial minority first renal transplant recipients. 2002 Transplant. Proc. pmid:12176508
Soylu H et al. Survival of renal transplant patients: data from a tertiary care center in Turkey. 2015 Transplant. Proc. pmid:25769571
Yamauchi M et al. Effects of FK506 on rat thymic microenvironment in thymocyte maturation, proliferation, and mobilization. 1998 Transplant. Proc. pmid:9838578
Mueller AR et al. Is the use of marginal liver grafts justified? 1999 Feb-Mar Transplant. Proc. pmid:10083160
Karakulska-Prystupiuk E et al. Pericarditis in Patients With Chronic Graft-vs-Host Disease. 2018 Transplant. Proc. pmid:30177139
Takeuchi H et al. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level. 2008 Transplant. Proc. pmid:18790203
Zipperle S et al. Impaired T-cell IL-10 secretion and CD4 helper function in liver transplant patients treated with tacrolimus. 1997 Feb-Mar Transplant. Proc. pmid:9123208
Sato K et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. 1989 Transplant. Proc. pmid:2468212
Freise CE et al. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. 1991 Transplant. Proc. pmid:1721397
McGrath JS and Shehata M The effect of differing immunosuppressive regimes on the functional and morphologic changes in a rat renal allograft model of chronic rejection. 2001 Transplant. Proc. pmid:11377499
Koefoed-Nielsen PB and Jørgensen KA Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. 2002 Transplant. Proc. pmid:12176559
Gasser M et al. Putative regulatory function of alloreactive Th2 cells in tolerant recipients after small bowel transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11266759
Jiang H et al. Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. 1999 Feb-Mar Transplant. Proc. pmid:10083538
Kahan BD High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. 1998 Transplant. Proc. pmid:9723224
Sheng H et al. Ocular complications of heart transplantation in a Chinese population. 2008 Transplant. Proc. pmid:19100445
Lauro A et al. Liver transplantation for familial amyloid polyneuropathy non-VAL30MET variants: are cardiac complications influenced by prophylactic pacing and immunosuppressive weaning? 2005 Transplant. Proc. pmid:15964382
Jiménez-Pérez M et al. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation. Transplant. Proc. pmid:25645779
MacDonald AS Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. 2003 Transplant. Proc. pmid:12742497
Sindhi R et al. Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. 2002 Transplant. Proc. pmid:12176644
Chakrabarti P et al. Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267274
Xu M et al. FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. 1998 Transplant. Proc. pmid:9723447
Maroun T et al. Rejection therapy with tacrolimus in renal transplantation: preliminary results of a collaborative multicenter study in 45 patients. Groupe Cooperatif de Transplantation D'ile de France (GCIF). 1998 Transplant. Proc. pmid:9745576
Martín-Fernández M et al. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. 2017 Transplant. Proc. pmid:29149986
Fung JJ and Starzl TE FK 506 in solid organ transplantation. 1994 Transplant. Proc. pmid:7524226
McCauley J et al. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. 1991 Transplant. Proc. pmid:1721459
Griffin AD et al. FK 506 in canine renal transplantation. 1992 Transplant. Proc. pmid:1384209
Filler G Optimization of immunosuppressive drug monitoring in children. 2007 Transplant. Proc. pmid:17524944
Ericzon BG et al. Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. 1991 Transplant. Proc. pmid:1703695